All In Biotech

Drug Trial Radar · NCT03891524

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

A Randomized, Open-Label, Study Drug-Dose Blind, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-70033093 (BMS-986177), an Oral Factor XIa Inhibitor, Versus Subcutaneous Enoxaparin in Subjects Undergoing Elective Total Knee Replacement Surgery

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,242 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,242

Actual

Start

Jun 17, 2019

Primary completion

Apr 6, 2021

Study completion Apr 6, 2021

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Mar 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy of JNJ-70033093 in preventing total venous thromboembolism (VTE) events (proximal and/or distal deep vein thrombosis \[DVT\] \[asymptomatic confirmed by venography assessment or objectively confirmed symptomatic\], nonfatal pulmonary embolism \[PE\], or any death) during the treatment period.

Conditions

  • Arthroplasty, Replacement, Knee

Interventions

  • JNJ-70033093 25 mgDrug

    Participants will receive JNJ-70033093 25 mg (1\*25 mg capsule) BID (in Group A) or once daily (in Group E), orally for 10 to 14 postoperative days.

  • JNJ-70033093 50 mgDrug

    Participants will receive JNJ-70033093 50 mg (2\*25 mg capsules) BID orally for 10 to 14 postoperative days.

  • JNJ-70033093 100 mgDrug

    Participants will receive JNJ-70033093 100 mg (1\*100 mg capsule) BID, orally for 10 to 14 postoperative days.

  • JNJ-70033093 200 mgDrug

    Participants will receive JNJ-70033093 200 mg (2\*100 mg capsules) BID (in Group D) or once daily (in Group F), orally for 10 to 14 postoperative days.

  • PlaceboDrug

    Participants will receive placebo matching to JNJ-70033093, orally.

  • Enoxaparin 40 mgDrug

    Participants will receive enoxaparin 40 mg once daily subcutaneously for 10 to 14 postoperative days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated)Time frame: Up to Day 14

Locations

117 sites in 18 countries. Site status is shown where the registry gives one.

  • Central Research Associates, Inc.

    Birmingham, Alabama

  • Arizona Research Center

    Phoenix, Arizona

  • Bowen Hefley Orthopedics

    Little Rock, Arkansas

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California

  • Denver Metro Orthopedics, PC

    Englewood, Colorado

  • DMI Research

    Pinellas Park, Florida

  • Gulfcoast Research Institute

    Sarasota, Florida

  • University Orthopedic and Joint Replacement Center

    Tamarac, Florida

  • Memorial Hermann Memorial City Medical Center

    Houston, Texas

  • Hospital Britanico de Buenos Aires

    Buenos Aires, Argentina

  • Clinica Adventista Belgrano

    CABA, Argentina

  • Hospital San Roque

    Córdoba, Argentina

  • Clínica Chutro

    Córdoba, Argentina

  • Hospital Italiano La Plata

    La Plata, Argentina

  • Instituto de Investigaciones Clinicas Rosario

    Rosario, Argentina

  • Sanatorio Corporación Médica de General San Martín

    San Martin, Argentina

  • ZNA Middelheim

    Antwerp, Belgium

  • Ziekenhuis Oost-Limburg

    Genk, Belgium

  • Jessa Ziekenhuis

    Hasselt, Belgium

  • ZNA Jan Palfijn

    Merksem, Belgium

  • Hospital Sao Francisco de Assis

    Belo Horizonte, Brazil

  • Hospital e Maternidade Dr Christovao da Gama S.A

    Santo André, Brazil

  • Hospital Estadual Mario covas

    Santo André, Brazil

  • University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski

    Pleven, Bulgaria

  • Acibadem City Clinic Tokuda Hospital

    Sofa, Bulgaria

  • University Multiprofile Hospital Sofiamed Sofia

    Sofia, Bulgaria

  • MHAT Tzaritza Joanna

    Sofia, Bulgaria

  • Medical Center - Medical Complex BEROE EOOD

    Stara Zagora, Bulgaria

  • Lakeridge Health

    Ajax, Ontario, Canada

  • Hamilton Health Sciences Corporation

    Hamilton, Ontario, Canada

  • The Ottawa Hospital Research Institute

    Ottawa, Ontario, Canada

  • Medical Investigative and Clinical Evaluation Inc

    Windsor, Ontario, Canada

  • General Hospital of Attiki 'KAT'

    Kifissia, Greece

  • General Hospital of Nea Ionia 'Konstantopoulio'

    Nea Ionia, Greece

  • University General Hospital of Rio Patras

    Pátrai, Greece

  • Papageorgiou General Hospital

    Thessaloniki, Greece

  • Semmelweis Egyetem

    Budapest, Hungary

  • Debreceni Egyetem

    Debrecen, Hungary

  • Petz Aladar Megyei Oktato Korhaz

    Gyõr, Hungary

  • Somogy Megyei Kaposi Mor Oktato Korhaz

    Kaposvár, Hungary

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.